SI1150686T1 - Directly compressible matrix for controlled release of single daily doses of clarithromycin - Google Patents

Directly compressible matrix for controlled release of single daily doses of clarithromycin

Info

Publication number
SI1150686T1
SI1150686T1 SI200030647T SI200030647T SI1150686T1 SI 1150686 T1 SI1150686 T1 SI 1150686T1 SI 200030647 T SI200030647 T SI 200030647T SI 200030647 T SI200030647 T SI 200030647T SI 1150686 T1 SI1150686 T1 SI 1150686T1
Authority
SI
Slovenia
Prior art keywords
clarithromycin
controlled release
daily doses
single daily
directly compressible
Prior art date
Application number
SI200030647T
Other languages
English (en)
Slovenian (sl)
Inventor
Temeljotov Darja Fercej
Milojka Mohar
Mateja Salobir
Ljubomira Barbara Rebic
Marko Opresnik
Original Assignee
Lek Farmacevtska Druzba D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Farmacevtska Druzba D.D. filed Critical Lek Farmacevtska Druzba D.D.
Publication of SI1150686T1 publication Critical patent/SI1150686T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200030647T 1999-02-19 2000-02-17 Directly compressible matrix for controlled release of single daily doses of clarithromycin SI1150686T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9900039A SI20150A (sl) 1999-02-19 1999-02-19 Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
PCT/SI2000/000002 WO2000048607A1 (en) 1999-02-19 2000-02-17 Directly compressible matrix for controlled release of single daily doses of clarithromycin

Publications (1)

Publication Number Publication Date
SI1150686T1 true SI1150686T1 (en) 2005-06-30

Family

ID=20432410

Family Applications (2)

Application Number Title Priority Date Filing Date
SI9900039A SI20150A (sl) 1999-02-19 1999-02-19 Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
SI200030647T SI1150686T1 (en) 1999-02-19 2000-02-17 Directly compressible matrix for controlled release of single daily doses of clarithromycin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI9900039A SI20150A (sl) 1999-02-19 1999-02-19 Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina

Country Status (21)

Country Link
EP (1) EP1150686B1 (xx)
AT (1) ATE286736T1 (xx)
AU (1) AU776912B2 (xx)
BG (1) BG65324B1 (xx)
CY (1) CY1107454T1 (xx)
CZ (1) CZ302781B6 (xx)
DE (1) DE60017361T2 (xx)
DK (1) DK1150686T3 (xx)
EE (1) EE05422B1 (xx)
ES (1) ES2235834T3 (xx)
HR (1) HRP20010684B1 (xx)
HU (1) HUP0105481A3 (xx)
PL (1) PL196665B1 (xx)
PT (1) PT1150686E (xx)
RS (1) RS50298B (xx)
RU (1) RU2237480C2 (xx)
SI (2) SI20150A (xx)
SK (1) SK287525B6 (xx)
TR (1) TR200102396T2 (xx)
UA (1) UA74778C2 (xx)
WO (1) WO2000048607A1 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200000054A2 (tr) * 2000-01-05 2001-08-21 Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
IN192748B (xx) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6673369B2 (en) 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
CA2405918A1 (en) * 2001-10-01 2003-04-01 Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
CA2465405A1 (en) 2001-11-02 2003-05-08 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
CN1652753A (zh) * 2002-04-03 2005-08-10 兰贝克赛实验室有限公司 具有改进的生物利用度的克拉霉素制剂
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
MXPA05001184A (es) * 2002-07-29 2005-09-12 Johnson & Johnson Formulaciones y formas de dosificacion para administracion controlada de topiramato.
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2005016278A2 (en) 2003-08-12 2005-02-24 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023221A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Clarithromycin formulations having improved biovailability
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
AU2005235237A1 (en) * 2004-03-24 2005-11-03 Lupin Limited Clarithromycin extended release formulation
EP2283824B1 (en) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) * 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60163823A (ja) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd 経口投与製剤
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS63188621A (ja) * 1987-01-30 1988-08-04 Taisho Pharmaceut Co Ltd 矯味経口製剤
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
IL87219A0 (en) * 1987-08-07 1988-12-30 Abbott Lab Erythromycin formulations for oral administration
JP2553882B2 (ja) * 1987-08-08 1996-11-13 富士写真光機株式会社 走査結像光学系
US5599556A (en) * 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
MX9603480A (es) * 1994-02-16 1997-12-31 Abbott Lab Procedimiento para preparar formulaciones farmaceuticas en particulas finas.

Also Published As

Publication number Publication date
PL350419A1 (en) 2002-12-16
PL196665B1 (pl) 2008-01-31
EE200100433A (et) 2002-12-16
HRP20010684B1 (en) 2011-01-31
WO2000048607A1 (en) 2000-08-24
PT1150686E (pt) 2005-05-31
BG105914A (bg) 2002-05-31
BG65324B1 (bg) 2008-02-29
TR200102396T2 (tr) 2002-01-21
DE60017361D1 (de) 2005-02-17
SK11972001A3 (sk) 2002-02-05
EE05422B1 (et) 2011-06-15
DK1150686T3 (da) 2005-04-04
SI20150A (sl) 2000-08-31
ES2235834T3 (es) 2005-07-16
CY1107454T1 (el) 2012-12-19
ATE286736T1 (de) 2005-01-15
DE60017361T2 (de) 2005-12-22
AU776912B2 (en) 2004-09-23
CZ302781B6 (cs) 2011-11-02
YU59201A (sh) 2004-07-15
HRP20010684A2 (en) 2002-10-31
EP1150686A1 (en) 2001-11-07
UA74778C2 (en) 2006-02-15
CZ20012964A3 (cs) 2002-01-16
HUP0105481A2 (hu) 2002-05-29
HUP0105481A3 (en) 2003-04-28
RS50298B (sr) 2009-09-08
EP1150686B1 (en) 2005-01-12
AU2704900A (en) 2000-09-04
RU2237480C2 (ru) 2004-10-10
SK287525B6 (sk) 2011-01-04

Similar Documents

Publication Publication Date Title
PL350419A1 (en) Directly compressible matrix for controlled release of single daily doses of clarithromycin
WO2001076370A3 (en) Anthelmintic combinations
AU3900300A (en) Improved aqueous solubility pharmaceutical formulations
MXPA02011632A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
BG106030A (en) Pharmaceutical composition
WO2001022791A3 (en) Controlled release compositions comprising nimesulide
WO2002017885A3 (en) Controlled release formulation of erythromycin or a derivative thereof
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
AP2003002716A0 (en) Medicinal compositions containing propenone derivatives.
NO20045385L (no) Farmasoytisk preparat inneholdende okskarbazepin med kontrollert frigivelse av aktivt stoff
WO2005065639A3 (en) Novel pharmaceutical compositions
AU2001227030A1 (en) Pharmaceutical composition for controlled release of an active ingredient
AU6386801A (en) System for the release of active ingredients
ES2176786T3 (es) Uso de extractos de ginkgo biloba para la preparacion de composicionesfarmaceuticas.
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
EP1550667A4 (en) AGENTS FOR REGULATING TYROSINASE ACTIVITY, PROCESS FOR PRODUCING SAID AGENTS AND EXTERNAL PREPARATIONS CONTAINING THE SAME
ZA981430B (en) Anticancer composition
EE9600202A (et) Toimeaine pärsitud vabanemisega karbamasepiini ravimvorm
WO2001022917A3 (en) Effervescent compositions comprising nimesulide
EP0729950A4 (en) ANTI-HIV MEDICINAL PRODUCTS
WO2002051419A3 (en) A pharmaceutical composition containing benzopyrano-oxopyrimidotetrahydrothiazine and its use in the treatment of hiv
IE780526L (en) Compositions for inhibiting male fertility
SE9902673D0 (sv) New composition
HUP0402446A2 (hu) Inszekticid premix és előállítása